AU2021455992A1 - Il1ra derived peptides for treatment of diabetic nephropathy - Google Patents

Il1ra derived peptides for treatment of diabetic nephropathy Download PDF

Info

Publication number
AU2021455992A1
AU2021455992A1 AU2021455992A AU2021455992A AU2021455992A1 AU 2021455992 A1 AU2021455992 A1 AU 2021455992A1 AU 2021455992 A AU2021455992 A AU 2021455992A AU 2021455992 A AU2021455992 A AU 2021455992A AU 2021455992 A1 AU2021455992 A1 AU 2021455992A1
Authority
AU
Australia
Prior art keywords
compound
amino acid
seq
use according
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021455992A
Other languages
English (en)
Inventor
Eva Steiness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serodus ApS
Original Assignee
Serodus ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus ApS filed Critical Serodus ApS
Publication of AU2021455992A1 publication Critical patent/AU2021455992A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2021455992A 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy Pending AU2021455992A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/069450 WO2023284947A1 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
AU2021455992A1 true AU2021455992A1 (en) 2024-01-18

Family

ID=76958978

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021455992A Pending AU2021455992A1 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Country Status (8)

Country Link
US (1) US20240216464A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351617B1 (cg-RX-API-DMAC7.html)
JP (1) JP7839260B2 (cg-RX-API-DMAC7.html)
CN (1) CN117642174A (cg-RX-API-DMAC7.html)
AU (1) AU2021455992A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226176A1 (cg-RX-API-DMAC7.html)
ES (1) ES3026437T3 (cg-RX-API-DMAC7.html)
WO (1) WO2023284947A1 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
MXPA05002514A (es) * 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
EP2686431B1 (en) 2011-03-14 2016-08-03 Phlogo ApS Antagonists of the interleukin- 1 receptor
WO2017063657A1 (en) 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist
US10041044B2 (en) * 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Also Published As

Publication number Publication date
JP2024525669A (ja) 2024-07-12
EP4351617C0 (en) 2025-03-26
JP7839260B2 (ja) 2026-04-01
EP4351617A1 (en) 2024-04-17
WO2023284947A1 (en) 2023-01-19
US20240216464A1 (en) 2024-07-04
ES3026437T3 (en) 2025-06-11
EP4351617B1 (en) 2025-03-26
CN117642174A (zh) 2024-03-01
CA3226176A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
Takashima et al. Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
CN109475592B (zh) 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物
CN1960758B (zh) 关节炎的治疗剂或预防剂
CN101541957B (zh) 利尿钠多肽
JP2021185178A (ja) 胆汁酸に関係した障害の治療方法
JP2003535037A (ja) 炎症を治療する方法
CN107090023B (zh) 一种选择性tnfr1拮抗肽sn10及其在类风湿性关节炎中的应用
CN105705160B (zh) Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
CA3150859A1 (en) Compositions, formulations, and interleukin production and purification
Zhang et al. Reversing CXCL10 deficiency ameliorates kidney disease in diabetic mice
EP4351617B1 (en) Il1ra derived peptides for treatment of diabetic nephropathy
US20220288054A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220401515A1 (en) Application of non-igf1r-binding substance in prevention and/or treatment of inflammatory diseases
EP3800196B1 (en) Peptide for treating rheumatoid arthritis and use thereof
CA3244198C (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
CN118420740A (zh) 一类半抗原和脂肪酸双修饰的BimBH3模拟肽及其制备方法和应用
EP4422659B1 (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
WO2014188373A1 (en) Chromogranin-a-derived polypeptides and methods of use
JP2004008027A (ja) cAMPの産生活性を有する新規ペプチド
WO2017063657A1 (en) Il1ra-derived peptide antagonist
Bonnet Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases 2
HK40005282A (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
AU2016371021A1 (en) Ameliorating systemic sclerosis with death receptor agonists
HK1138333A (en) Methods of diagnosing and treating an inflammatory response